Not provided
Not provided
Not provided
Not provided
Not provided
No longer studying long COVID
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Hudson Valley Healing Arts Center | UNKNOWN |
Not provided
Not provided
Not provided
The purpose of this research study is to assess if glutathione, along with NAC (N-acetyl cysteine) and Alpha lipoic acid (ALA), can help reverse some of the COVID long-haul symptoms.Subjects will be randomized in to one of two groups. Depending on the group they are randomized in to, subjects will be taking either a combination of NAC, Alamax CR, and liposomal GSH or the same three nutritional supplements with a multivitamin and magnesium. Regardless of the group, subjects will be asked questions to assess their COVID symptoms, physical and mental health status. They will also be asked to take blood samples.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| No Multivitamin and Magnesium | Experimental | Subjects randomized into Group A will take the following amount for 28 days
|
|
| Multivitamin and Magnesium | Active Comparator | Subjects randomized into Group B will be taking a multivitamin and magnesium for 14 days. Afterwards, they will take the following for 14 days.
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| NAC (N-acetyl cysteine), Alpha lipoic acid (ALA), liposomal glutathione (GSH) | Drug | Nutritional supplements hypothesized to help reverse some of the COVID long-haul symptoms. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Assess Changes in Symptoms of Post-Acute Sequelae of COVID (PASC) | With the goal of reversing symptoms of Post-Acute Sequelae of COVID, this outcome measure aims to evaluate changes in symptoms before and after therapy, and determining which, if any symptoms are improved in each arm of the trial. | Symptoms will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy |
| Change in Quality of Life Using SF-36 Survey | The SF-36 survey is a multipurpose, short-form health survey with 36 questions to evaluate health-related Quality of Life . It yields an eight-scale profile of scores as well as physical and mental health summary measures. It is a generic measure, as opposed to one that targets a specific age, disease, or treatment group. | Will be evaluated at 2 weeks, 1-, 2-, 3- and 4 months post therapy |
| COVID Severity of Symptoms Questionnaire | This will evaluate the changes in the severity of symptoms over time with treatment. | Day 15, 28, end of months 2, 3, 4 |
| Change in Time to Clinical Recovery (TTCR) | Starting on day one of subjects' treatment, subjects will be asked if symptoms have improved or worsened, and the time it took for symptoms to change since their last treatment: (0 [no change], +1 [improved within 7 days], + 2 [improved within 14 days], +3 [improved within 28 days] + 4 [symptom resolved]; - 1 [worsened within 7 days], -2 [worsened within 14 days], - 3 [worsened within 28 days], - 4 [debilitating last 28 days] | Day 15 and 28 (month 1), and at the end of months 2, 3 and 4 |
Not provided
Not provided
Inclusion Criteria:
• Patients with positive COVID testing (AB, RT PCR) and mild-severe symptoms based on COVID symptom list
Exclusion Criteria:
• History of a severe sulfa sensitivity (i.e., anaphylaxis, Stevens Johnson Syndrome), allergy to meat products and/or gelatin (alpha gal allergy) and/or a history of an allergic or adverse reaction to NAC, alpha lipoic acid and/or GSH.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of California Irvine Medical Center | Orange | California | 92868 | United States |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D000086382 | COVID-19 |
| D000094024 | Post-Acute COVID-19 Syndrome |
| ID | Term |
|---|---|
| D011024 | Pneumonia, Viral |
| D011014 | Pneumonia |
| D012141 | Respiratory Tract Infections |
| D007239 | Infections |
Not provided
Not provided
| ID | Term |
|---|---|
| D000111 | Acetylcysteine |
| D008063 | Thioctic Acid |
| D005978 | Glutathione |
| ID | Term |
|---|---|
| D003545 | Cysteine |
| D000603 | Amino Acids, Sulfur |
| D013457 | Sulfur Compounds |
| D009930 | Organic Chemicals |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| D014777 |
| Virus Diseases |
| D018352 | Coronavirus Infections |
| D003333 | Coronaviridae Infections |
| D030341 | Nidovirales Infections |
| D012327 | RNA Virus Infections |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D000094025 | Post-Infectious Disorders |
| D002908 | Chronic Disease |
| D020969 | Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D000596 |
| Amino Acids |
| D000602 | Amino Acids, Peptides, and Proteins |
| D002264 | Carboxylic Acids |
| D013876 | Thiophenes |
| D003067 | Coenzymes |
| D045762 | Enzymes and Coenzymes |
| D005227 | Fatty Acids |
| D008055 | Lipids |
| D009842 | Oligopeptides |
| D010455 | Peptides |